{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:34:25Z","timestamp":1789929265378,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Gen Psychiatry"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To compare the costs and effects of paliperidone extended release (ER), a new pharmaceutical treatment for the management of schizophrenia, with the most frequently prescribed oral treatments in Greece (namely risperidone, olanzapine, quetiapine, aripiprazole and ziprasidone) over a 1-year time period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A decision tree was developed and tailored to the specific circumstances of the Greek healthcare system. Therapeutic effectiveness was defined as the annual number of stable days and the clinical data was collected from international clinical trials and published sources. The study population was patients who suffer from schizophrenia with acute exacerbation. During a consensus panel of 10 psychiatrists and 6 health economists, data were collected on the clinical practice and medical resource utilisation. Unit costs were derived from public sources and official reimbursement tariffs. For the comparators official retail prices were used. Since a price had not yet been granted for paliperidone ER at the time of the study, the conservative assumption of including the average of the highest targeted European prices was used, overestimating the price of paliperidone ER in Greece. The study was conducted from the perspective of the National Healthcare System.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The data indicate that paliperidone ER might offer an increased number of stable days (272.5 compared to 272.2 for olanzapine, 265.5 f risperidone, 260.7 for quetiapine, 260.5 for ziprasidone and 258.6 for aripiprazole) with a lower cost compared to the other therapies examined (\u20ac7,030 compared to \u20ac7,034 for olanzapine, \u20ac7,082 for risperidone, \u20ac8,321 for quetiapine, \u20ac7,713 for ziprasidone and \u20ac7,807 for aripiprazole). During the sensitivity analysis, a \u00b1 10% change in the duration and frequency of relapses and the economic parameters did not lead to significant changes in the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with paliperidone ER can lead to lower total cost and higher number of stable days in most of the cases examined.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1744-859x-7-16","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T18:13:39Z","timestamp":1219947219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study"],"prefix":"10.1186","volume":"7","author":[{"given":"Maria","family":"Geitona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hara","family":"Kousoulakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Ollandezos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Athanasakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiria","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kyriopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8510(99)00078-0","volume":"51","author":"R Tarricone","year":"2000","unstructured":"Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G: Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy. 2000, 51: 1-18. 10.1016\/S0168-8510(99)00078-0.","journal-title":"Health Policy"},{"key":"606_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1192\/pb.14.9.522","volume":"14","author":"L Davies","year":"1990","unstructured":"Davies L, Drummond M: The economic burden of schizophrenia. Psychiatr Bull. 1990, 14: 522-525. 10.1192\/pb.14.9.522.","journal-title":"Psychiatr Bull"},{"key":"606_CR3","first-page":"3917","volume":"94","author":"JE Cooper","year":"1991","unstructured":"Cooper JE: Schizophrenia and allied condition. Med Int. 1991, 94: 3917-3922.","journal-title":"Med Int"},{"key":"606_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1192\/bjp.171.6.509","volume":"171","author":"M Knapp","year":"1997","unstructured":"Knapp M: Costs of schizophrenia. Br J Psychiatry. 1997, 171: 509-518.","journal-title":"Br J Psychiatry"},{"key":"606_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00019053-199508030-00004","volume":"8","author":"KG Terkelsen","year":"1995","unstructured":"Terkelsen KG, Menikoff A: Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. Pharmacoeconomics. 1995, 8: 199-222.","journal-title":"Pharmacoeconomics"},{"key":"606_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","volume":"30","author":"M Knapp","year":"2004","unstructured":"Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull. 2004, 30: 279-293.","journal-title":"Schizophr Bull"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00019053-200422030-00002","volume":"22","author":"L Ettaro","year":"2004","unstructured":"Ettaro L, Songer TJ, Zhang P, Engelgau MM: Cost of illness studies in diabetes mellitus. Pharmacoeconomics. 2004, 22: 149-164. 10.2165\/00019053-200422030-00002.","journal-title":"Pharmacoeconomics"},{"key":"606_CR8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00789054","volume":"30","author":"RJ Wyatt","year":"1995","unstructured":"Wyatt RJ, Henter I, Leary MC, Taylor E: An economic evaluation of schizophrenia \u2013 1991. Soc Psychiatry Psychiatr Epidemiol. 1995, 30: 196-205.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"606_CR9","volume-title":"Kaplan and Sadock's synopsis of psychiatry: behavioral sciences, clinical psychiatry","author":"BJ Sadock","year":"2003","unstructured":"Sadock BJ, Sadock VA: Kaplan and Sadock's synopsis of psychiatry: behavioral sciences, clinical psychiatry. 2003, Philadelphia, PA: Lippincott, Williams and Wilkins, 9","edition":"9"},{"key":"606_CR10","volume-title":"Schizophrenia, Psychiatry","author":"A Rabavilas","year":"2000","unstructured":"Rabavilas A, Christodoulou GN: Schizophrenia, Psychiatry. 2000, Editions of the Psychiatric Clinic of the University of Athens: publisher Beta, Athens"},{"key":"606_CR11","unstructured":"National Institute of Mental Health: Schizophrenia. [http:\/\/www.nimh.nihgov\/publicat\/schizoph.cfm?Output=Print]"},{"key":"606_CR12","volume-title":"Practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2004","unstructured":"American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. 2004, Arlington, VA: American Psychiatric Association, 2","edition":"2"},{"key":"606_CR13","doi-asserted-by":"crossref","unstructured":"Knapp M: Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl. 2000, 15-18. 407","DOI":"10.1046\/j.1467-0658.2001.00137.x-i1"},{"key":"606_CR14","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1185\/030079905X75087","volume":"21","author":"R Goeree","year":"2005","unstructured":"Goeree R, Farahati F, Burke N, Blackhouse G, O' Reilly D, Pyne J, Tarride JE: The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005, 21: 2017-2028. 10.1185\/030079905X75087.","journal-title":"Curr Med Res Opin"},{"key":"606_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"606_CR16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1517\/14656566.8.14.2307","volume":"8","author":"H Dlugosz","year":"2007","unstructured":"Dlugosz H, Nasrallah HA: Paliperidone: a new extended-release oral atypical antipsychotic. Exp Opin Pharmacother. 2007, 8: 2307-2313. 10.1517\/14656566.8.14.2307.","journal-title":"Exp Opin Pharmacother"},{"issue":"5","key":"606_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3928\/02793695-20070501-05","volume":"45","author":"RH Howland","year":"2007","unstructured":"Howland RH: Paliperidone extended-release tablets: a new atypical antipsychotic. J Psychosoc Nurs Ment Health Serv. 2007, 45 (5): 15-18.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"606_CR18","volume-title":"Neuropsychiatr Dis Treat","author":"PG Janicak","year":"2007","unstructured":"Janicak PG, Winans EA: Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007, 6:"},{"key":"606_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.pnpbp.2006.03.031","volume":"30","author":"S Keith","year":"2006","unstructured":"Keith S: Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30: 996-1008. 10.1016\/j.pnpbp.2006.03.031.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"606_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1358\/dot.2007.43.4.1067342","volume":"43","author":"RT Owen","year":"2007","unstructured":"Owen RT: Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc). 2007, 43: 249-258. 10.1358\/dot.2007.43.4.1067342.","journal-title":"Drugs Today (Barc)"},{"key":"606_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007, 90: 147-161. 10.1016\/j.schres.2006.09.012.","journal-title":"Schizophr Res"},{"key":"606_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007, 62: 1363-1370. 10.1016\/j.biopsych.2007.01.017.","journal-title":"Biol Psychiatry"},{"key":"606_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007, 93: 117-130. 10.1016\/j.schres.2007.03.003.","journal-title":"Schizophr Res"},{"key":"606_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","volume":"27","author":"M Kramer","year":"2007","unstructured":"Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007, 27: 6-14. 10.1097\/JCP.0b013e31802dda4a.","journal-title":"J Clin Psychopharmacol"},{"key":"606_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00023210-200721050-00005","volume":"21","author":"LP Yang","year":"2007","unstructured":"Yang LP, Plosker GL: Paliperidone extended release. CNS Drugs. 2007, 21: 417-425. 10.2165\/00023210-200721050-00005.","journal-title":"CNS Drugs"},{"key":"606_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1517\/14740338.6.6.651","volume":"6","author":"E Spina","year":"2007","unstructured":"Spina E, Cavallaro R: The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf. 2007, 6: 651-662. 10.1517\/14740338.6.6.651.","journal-title":"Expert Opin Drug Saf"},{"key":"606_CR27","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1185\/030079906X132613","volume":"22","author":"R Conley","year":"2006","unstructured":"Conley R, Gupta S: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006, 22: 1879-1892. 10.1185\/030079906X132613.","journal-title":"Curr Med Res Opin"},{"key":"606_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ps.51.2.216","volume":"51","author":"M Olfson","year":"2000","unstructured":"Olfson M, Mechanic D, Hansell S, Bover CA, Walkup J, Weiden PJ: Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psych Serv. 2000, 51: 216-222. 10.1176\/appi.ps.51.2.216.","journal-title":"Psych Serv"},{"key":"606_CR29","first-page":"49","volume":"18","author":"M Geitona","year":"2007","unstructured":"Geitona M, Papanicolaou S, Aggelopoulos E, Ollandezos M, Kousoulakou C, Aggelopoulos E, Zaharakis K, Kakavas P, Karpouza B, Kesidou S, Bilanakis N, Papamichael E, Chaidemenos A, Chamogeorgakis T, Kyriopoulos J: Treatment patterns and cost assessment of schizophrenia in Greece. Psychiatry. 2007, 18: 49-60.","journal-title":"Psychiatry"},{"key":"606_CR30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7175\/fe.v9i2.221","volume":"9","author":"P Berto","year":"2008","unstructured":"Berto P, Negrini C, Ferrannini L: Analisi costo-efficacia di paliperidone ER nel trattamento della ricadute della schizopfrenia, nella prospettiva del Sistema Sanitario Nazionale italiano. Farmacoeconomia e percorsi terapeutici. 2008, 9: 95-108.","journal-title":"Farmacoeconomia e percorsi terapeutici"},{"key":"606_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","volume":"158","author":"RR Conley","year":"2001","unstructured":"Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001, 158: 765-774. 10.1176\/appi.ajp.158.5.765.","journal-title":"Am J Psychiatry"},{"key":"606_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1524-4733.2004.75008.x","volume":"7","author":"M Vera-Llonch","year":"2004","unstructured":"Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G: Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health. 2004, 7: 569-584. 10.1111\/j.1524-4733.2004.75008.x.","journal-title":"Value Health"},{"key":"606_CR33","first-page":"213","volume":"28","author":"RL Borison","year":"1992","unstructured":"Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992, 28: 213-218.","journal-title":"Psychopharmacol Bull"},{"key":"606_CR34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1176\/ajp.151.6.825","volume":"151","author":"SR Marder","year":"1994","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994, 151: 825-835.","journal-title":"Am J Psychiatry"},{"key":"606_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito GG, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003, 60: 681-690. 10.1001\/archpsyc.60.7.681.","journal-title":"Arch Gen Psychiatry"},{"key":"606_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02245617","volume":"124","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berlin). 1996, 124: 159-167. 10.1007\/BF02245617.","journal-title":"Psychopharmacology (Berlin)"},{"key":"606_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","volume":"14","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996, 14: 111-123. 10.1016\/0893-133X(95)00069-P.","journal-title":"Neuropsychopharmacology"},{"key":"606_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0149-2918(95)80102-2","volume":"17","author":"LF Fabre","year":"1995","unstructured":"Fabre LF, Arvanitis L, Pultz J, Jones vm, Malick JB, Stotnick VB: ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Therapeut. 1995, 17: 366-378. 10.1016\/0149-2918(95)80102-2.","journal-title":"Clin Therapeut"},{"key":"606_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","volume":"16","author":"RL Borison","year":"1996","unstructured":"Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicentre, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol. 1996, 16: 158-169. 10.1097\/00004714-199604000-00008.","journal-title":"J Clin Psychopharmacol"},{"key":"606_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","volume":"54","author":"JG Small","year":"1997","unstructured":"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997, 54: 549-557.","journal-title":"Arch Gen Psychiatry"},{"key":"606_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","volume":"42","author":"LA Arvanitis","year":"1997","unstructured":"Arvanitis LA, Miller BG: Multiple fixed doses of \"Seroquel\" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997, 42: 233-246. 10.1016\/S0006-3223(97)00190-X.","journal-title":"Biol Psychiatry"},{"key":"606_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/00005053-199211000-00007","volume":"180","author":"M Bell","year":"1992","unstructured":"Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D: The positive and negative syndrome scale and the brief psychiatric rating scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992, 180: 723-728.","journal-title":"J Nerv Ment Dis"},{"key":"606_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s002130050755","volume":"140","author":"P Keck","year":"1998","unstructured":"Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrisey MR: Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology. 1998, 140: 173-184. 10.1007\/s002130050755.","journal-title":"Psychopharmacology"},{"key":"606_CR44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","volume":"20","author":"DG Daniel","year":"1999","unstructured":"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999, 20: 491-505. 10.1016\/S0893-133X(98)00090-6.","journal-title":"Neuropsychopharmacology"},{"key":"606_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","volume":"17","author":"M Arato","year":"2002","unstructured":"Arato M, O'Connor R, Meltzer HY: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the ziprasidone extended use in schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002, 17: 207-215. 10.1097\/00004850-200209000-00001.","journal-title":"Int Clin Psychopharmacol"},{"key":"606_CR46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002, 63: 763-771.","journal-title":"J Clin Psychiatry"},{"key":"606_CR47","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","volume":"64","author":"TA Pigott","year":"2003","unstructured":"Pigott TA, Carson WH, Saha AR, Torbevns AF, Stock EG, Ingenito GG, Aripiprazole Study Group: Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003, 64: 1048-1056.","journal-title":"J Clin Psychiatry"},{"key":"606_CR48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4088\/JCP.v66n0810","volume":"66","author":"M Dossenbach","year":"2005","unstructured":"Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S: Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005, 66: 1021-1030.","journal-title":"J Clin Psychiatry"},{"key":"606_CR49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, the CATIE Investigators: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006, 163: 611-622. 10.1176\/appi.ajp.163.4.611.","journal-title":"Am J Psychiatry"},{"key":"606_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1176\/appi.ps.54.5.719","volume":"54","author":"J Menzin","year":"2003","unstructured":"Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003, 54: 719-723. 10.1176\/appi.ps.54.5.719.","journal-title":"Psychiatr Serv"},{"key":"606_CR51","unstructured":"IMS health. [http:\/\/www.IMShealth.com]"},{"key":"606_CR52","unstructured":"Social Insurance Fund Tariffs. [http:\/\/www.ika.gr\/gr\/infopages\/asf\/benefits\/kind2money.cfm]"},{"key":"606_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2165\/00019053-200523001-00006","volume":"23","author":"PS Chue","year":"2005","unstructured":"Chue PS, Bart MS, Buskens E, van Hout BA: Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics. 2005, 23: 62-74. 10.2165\/00019053-200523001-00006.","journal-title":"Pharmacoeconomics"},{"key":"606_CR54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/00019053-199813050-00010","volume":"13","author":"S Almond","year":"1998","unstructured":"Almond S, O'Donnell O: Cost analysis of the treatment of schizophrenia in the UK. A comparison of olanzapine and haloperidol. Pharmacoeconomics. 1998, 13: 575-588. 10.2165\/00019053-199813050-00010.","journal-title":"Pharmacoeconomics"},{"key":"606_CR55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0920-1211(95)00090-9","volume":"23","author":"MI Murray","year":"1996","unstructured":"Murray MI, Halpern MT, Leppik IE: Cost of refractory epilepsy in adults in the USA. Epilepsy Res. 1996, 23: 139-148. 10.1016\/0920-1211(95)00090-9.","journal-title":"Epilepsy Res"},{"key":"606_CR56","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2165\/00019053-199916060-00008","volume":"16","author":"JM Plumb","year":"1999","unstructured":"Plumb JM, Guest JF: Annual cost of erectile dysfunction to UK society. Pharmacoeconomics. 1999, 16: 699-709. 10.2165\/00019053-199916060-00008.","journal-title":"Pharmacoeconomics"},{"key":"606_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1478-7547-4-10","volume":"4","author":"A Boscoe","year":"2006","unstructured":"Boscoe A, Paramore C, Verbalis JG: Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006, 4: 10-10.1186\/1478-7547-4-10.","journal-title":"Cost Eff Resour Alloc"},{"key":"606_CR58","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/016327878200500206","volume":"5","author":"SA Mazzuca","year":"1982","unstructured":"Mazzuca SA, Cohen SJ: Scoring patient management problems: external validation of expert consensus. Eval Health Prof. 1982, 5: 210-217. 10.1177\/016327878200500206.","journal-title":"Eval Health Prof"},{"key":"606_CR59","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/0002-8703(78)90151-5","volume":"96","author":"ME Sanmarco","year":"1978","unstructured":"Sanmarco ME, Brooks SH, Blankenhorn DH: Reproducibility of a consensus panel in the interpretation of coronary angiograms. Am Heart J. 1978, 96: 430-437. 10.1016\/0002-8703(78)90151-5.","journal-title":"Am Heart J"},{"key":"606_CR60","unstructured":"Official Government Gazette 2005: 1869, National Publishing Office, Athens, Greece"}],"updated-by":[{"DOI":"10.1186\/1744-859x-8-15","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,6,18]],"date-time":"2009-06-18T00:00:00Z","timestamp":1245283200000}}],"container-title":["Annals of General Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1744-859X-7-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T18:36:43Z","timestamp":1738348603000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals-general-psychiatry.biomedcentral.com\/articles\/10.1186\/1744-859X-7-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1186\/1744-859x-7-16","relation":{},"ISSN":["1744-859X"],"issn-type":[{"value":"1744-859X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]},"assertion":[{"value":"4 February 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"16"}}